CN Patent

CN113583001A — 依鲁替尼的制备

Assigned to Nanjing Junruo Biomedical Research Institute Co ltd · Expires 2021-11-02 · 5y expired

What this patent protects

本发明涉及依鲁替尼的制备工艺。具体为化合物式I(5‑氨基‑3‑(4‑苯氧基苯基)‑1H‑吡唑‑4‑甲腈)和化合物式II((S)‑1‑(3‑羟基哌啶‑1‑基)丙‑2‑烯‑1‑酮)发生Mitsunobu缩合反应，得到化合物式III((R)‑1‑(1‑丙烯酰基哌啶‑3‑基)‑5‑氨基‑3‑(4‑苯氧基苯基)‑1H‑吡唑‑4‑甲腈),随后化合物式III和甲酰胺反应，制备得到依鲁替尼。

USPTO Abstract

本发明涉及依鲁替尼的制备工艺。具体为化合物式I(5‑氨基‑3‑(4‑苯氧基苯基)‑1H‑吡唑‑4‑甲腈)和化合物式II((S)‑1‑(3‑羟基哌啶‑1‑基)丙‑2‑烯‑1‑酮)发生Mitsunobu缩合反应，得到化合物式III((R)‑1‑(1‑丙烯酰基哌啶‑3‑基)‑5‑氨基‑3‑(4‑苯氧基苯基)‑1H‑吡唑‑4‑甲腈),随后化合物式III和甲酰胺反应，制备得到依鲁替尼。

Drugs covered by this patent

Patent Metadata

Patent number
CN113583001A
Jurisdiction
CN
Classification
—
Expires
2021-11-02
Drug substance claim
No
Drug product claim
No
Assignee
Nanjing Junruo Biomedical Research Institute Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.